CD19 CAR-T Cell Therapy at the LMU Munich from 2019 to 2021: Increasing Therapy Safety over the Years

被引：0

作者：

Bucklein, V ^{[1
,2
,3
]}

Blumenberg, V ^{[1
,2
,4
]}

Frolich, L. ^{[1
,4
]}

Ackermann, J. ^{[1
]}

Schmidt, C. ^{[1
]}

Hildebrand, F. ^{[1
,2
]}

Rejeski, K. ^{[1
,2
,4
]}

Winkelmann, M. ^{[5
]}

Schoberl, F. ^{[6
]}

Kunz, W.

Von Baumgarten, L. ^{[1
,3
,7
]}

Humpe, A. ^{[8
]}

Von Bergwelt, M. ^{[3
,4
]}

Subklewe, M. ^{[1
,2
,3
,4
]}

机构：

[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany

[2] LMU Gene Ctr, Lab Translat Canc Immunol, Munich, Germany

[3] Bavarian Canc Res Ctr BZKF, Munich, Germany

[4] German Canc Consortium DKTK, German Canc Res Ctr DKFZ, Heidelberg, Germany

[5] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiol, Munich, Germany

[6] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Neurol, Munich, Germany

[7] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Neurosurg, Munich, Germany

[8] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Transfus Med, Munich, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P388

引用

页码：125 / 125

页数：1

共 50 条

[21] GENOMIC DRIVERS OF LARGE B-CELL LYMPHOMA RESISTANCE TO CD19 CAR-T THERAPY
Jain, Michael
Ziccheddu, Bachisio
Coughlin, Caroline
Faramand, Rawan
Griswold, Anthony
Reid, Kayla
Landgren, Ola
Locke, Frederick
Maura, Francesco
Davila, Marco
Schatz, Jonathan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A703 - A703
[22] Clinical Trial of CD19 CAR-T Cell Therapy with non-virus Vector System
Takahashi, Yoshiyuki
PEDIATRIC BLOOD & CANCER, 2017, 64 : S3 - S3
[23] Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Lihong An
Yuehui Lin
Biping Deng
Zhichao Yin
Defeng Zhao
Zhuojun Ling
Tong Wu
Yongqiang Zhao
Alex H. Chang
Chunrong Tong
Shuangyou Liu
BMC Cancer, 22
[24] Two years later: CD19 CAR-T going the distance
Darnell, Eli P.
Frigault, Matthew J.
BLOOD, 2024, 143 (05) : 379 - 380
[25] Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
Rejeski, Kai
Perez, Ariel
Iacoboni, Gloria
Blumenberg, Viktoria
Buecklein, Veit L.
Voelkl, Simon
Penack, Olaf
Albanyan, Omar
Stock, Sophia
Mueller, Fabian
Karschnia, Philipp
Petrera, Agnese
Reid, Kayla
Faramand, Rawan
Davila, Marco L.
Modi, Karnav
Dean, Erin A.
Bachmeier, Christina
von Bergwelt-Baildon, Michael
Locke, Frederick L.
Bethge, Wolfgang
Bullinger, Lars
Mackensen, Andreas
Barba, Pere
Jain, Michael D.
Subklewe, Marion
SCIENCE ADVANCES, 2023, 9 (38)
[26] Continuous B cell destruction and regeneration is crucial for effective response to anti CD19 CAR-T cell therapy
Nevo, Neta
Milman, Neta
Cooper, Tim J.
Zuckerman, Tsila
Shen-Orr, Shai S.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 761 - 761
[27] Infectious complications among CD19 CAR-T cell therapy recipients: A single-center experience
Walker, Bryan
Zimmer, Andrea J.
Stohs, Erica J.
Lunning, Matthew
Lyden, Elizabeth
Abbas, Anum
TRANSPLANT INFECTIOUS DISEASE, 2023, 25
[28] Reduced ABO blood group antibody titers in patients after CD19 CAR-T cell therapy
Li, Qiang
Yang, Zhihuan
Fang, Kuo
Wei, Shuning
Sun, Jiali
Liu, Wei
Chen, Xiaojuan
Huang, Wenyang
Zhang, Guangji
Shi, Yin
Liu, Yuntao
Gong, Xiaoyuan
Liu, Fang
Zhou, Xueli
Wang, Jianxiang
Wang, Ying
BLOOD SCIENCE, 2023, 5 (01): : 62 - 65
[29] Infectious complications among CD19 CAR-T cell therapy recipients: A single-center experience
Walker, Bryan
Zimmer, Andrea J.
Stohs, Erica J.
Lunning, Matthew
Lyden, Elizabeth
Abbas, Anum
TRANSPLANT INFECTIOUS DISEASE, 2023, 25
[30] CD19 CAR T cell therapy effective for systemic lupus erythematosus
Gelfand, J.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (01) : 4 - 4

← 1 2 3 4 5 →